Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$109.21 – a decrease of 1.76% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013. So if you had owned 4798 shares the day before the split, the next day you would own 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.
| 52-week range | US$89.2389 - US$121.64 |
|---|---|
| 50-day moving average | US$114.8906 |
| 200-day moving average | US$106.6625 |
| Target price | US$126.74 |
| PE ratio | 34.4908 |
| Dividend yield | US$2.08 (1.96%) |
| Earnings per share (TTM) | US$3.26 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $109.21
| 1 week (2024-04-11) | -2.01% |
|---|---|
| 1 month (2024-03-18) | -2.87% |
| 3 months (2024-01-18) | -4.22% |
| 6 months (2023-10-18) | 14.28% |
| 1 year (2023-04-17) | 4.49% |
|---|---|
| 2 years (2022-04-14) | -7.21% |
| 3 years (2021-04-16) | -12.18% |
| 5 years (2019-04-18) | 47.74% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Abbott Laboratories shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 39.3758. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$10.5 billion (£8.4 billion).
The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$89.2389 up to US$121.64. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.74. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).
| Revenue TTM | US$40.1 billion |
|---|---|
| Operating margin TTM | 20.09% |
| Gross profit TTM | US$24.6 billion |
| Return on assets TTM | 6.11% |
| Return on equity TTM | 15.11% |
| Profit margin | 14.27% |
| Book value | 22.261 |
| Market capitalisation | US$195.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 47.75% of net profits
Recently Abbott Laboratories has paid out, on average, around 47.75% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.96% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.08 per share.
While Abbott Laboratories's payout ratio might seem fairly standard, it's worth remembering that Abbott Laboratories may be investing much of the rest of its net profits in future growth.
Abbott Laboratories's most recent dividend payout was on 14 May 2024. The latest dividend was paid out to all shareholders who bought their shares by 11 April 2024 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 32.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.98/100
Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 20.71/100
Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.15/100
Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.
Abbott Laboratories was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.35 |
|---|---|
| Total ESG percentile | 60.66 |
| Environmental score | 3.98 |
| Environmental score percentile | 5 |
| Social score | 20.71 |
| Social score percentile | 5 |
| Governance score | 13.15 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
